Cargando…

YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas

Epidermal growth factor receptor (EGFR) mutations are found in lung adenocarcinomas leading to tumor cells proliferation and survival. EGFR tyrosine kinase inhibitors (TKIs) that block EGFR activity are effective therapeutics for EGFR-mutant lung adenocarcinoma patients, but TKI-resistance inevitabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ting-Fang, Tseng, Yu-Chi, Chang, Wei-Chin, Chen, Yi-Chen, Kao, Yu-Rung, Chou, Teh-Ying, Ho, Chao-Chi, Wu, Cheng-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685690/ https://www.ncbi.nlm.nih.gov/pubmed/29163769 http://dx.doi.org/10.18632/oncotarget.19647

Ejemplares similares

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma
por: Lin, Erh-Hsuan, et al.
Publicado: (2016)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
por: Chiu, Chao-Hua, et al.
Publicado: (2015)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs
por: Ho, Hsiang-Ling, et al.
Publicado: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination
por: Hsiao, Shih-Hsin, et al.
Publicado: (2017)

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
por: Park, Hee Sun, et al.
Publicado: (2021)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

YAP-Dependent BiP Induction Is Involved in Nicotine-Mediated Oral Cancer Malignancy
por: Chien, Chu-Yen, et al.
Publicado: (2021)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells
por: Chen, Tzu-Chi, et al.
Publicado: (2013)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
por: Ho, Hsiang-Ling, et al.
Publicado: (2019)

Synthetic dysmobility screen unveils an integrated STK40-YAP-MAPK system driving cell migration
por: Yu, Ling-Yea, et al.
Publicado: (2021)

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
por: Hung, Hsiu-Ying, et al.
Publicado: (2016)

Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy
por: Chiang, Chi-Lu, et al.
Publicado: (2017)

Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression
por: Wang, Mong-Lien, et al.
Publicado: (2020)

Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses
por: Su, Sheng-Fang, et al.
Publicado: (2021)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer
por: Huang, Changhao, et al.
Publicado: (2020)

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
por: Chen, Hsuan-Yu, et al.
Publicado: (2016)

Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications
por: Sun, Tianai, et al.
Publicado: (2020)

Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice
por: Su, Kang-Yi, et al.
Publicado: (2016)

Cisd2 is essential to delaying cardiac aging and to maintaining heart functions
por: Yeh, Chi-Hsiao, et al.
Publicado: (2019)

Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma
por: Zhang, Xiao, et al.
Publicado: (2021)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

EGFR Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities
por: Lin, Tzu-Yin, et al.
Publicado: (2022)

Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Recent Progress in Metabolic Syndrome Research and Therapeutics
por: Kao, Ting-Wei, et al.
Publicado: (2021)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

YAP in pancreatic cancer: oncogenic role and therapeutic strategy
por: Mao, Wenhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l8aj7a5m5sc17e6eaqnp0kisb9